Abstracts

LONG-TERM OUTCOMES OF DOLUTEGRAVIR AND EFAVIRENZ-400 AS FIRST-LINE ART IN CAMEROON

WHO recommends dolutegravir 50mg (DTG) as first-line antiretroviral treatment (ART) and efavirenz 400mg (EFV400) as second option since 2019. Both ART efficacy and safety in real living conditions in low- and middle-income countries (LMIC) were previously demonstrated by the NAMSAL study group and provided solid elements for these recommendations. Nevertheless, only after three years of…

B/F/TAF FIVE-YEAR OUTCOMES IN TREATMENT-NAÏVE ADULTS

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a guidelines-recommended single-tablet regimen for people with HIV-1 (PWH). We present 5-year cumulative outcomes of two phase 3 studies of B/F/TAF in treatment-naïve PWH. We conducted 2 randomized, double-blind, phase 3 studies of B/F/TAF in treatment-naïve adults – Study 1489 (1489): B/F/TAF vs DTG/ABC/3TC and Study 1490 (1490): B/F/TAF vs DTG+F/TAF.…

HIV-1 RNA DECAY IN SEMEN AND RECTUM WITH DTG PLUS 3TC VERSUS BIC/FTC/TAF

The assessment of HIV decay kinetics in genital fluids and rectum may assist in predicting the potential risk of sexual transmission after initiating antiretroviral therapy (ART). HIV decay in semen and rectum have not yet been described for the dual combination dolutegravir (DTG) plus lamivudine (3TC). Open-label, multicenter, randomized, pilot clinical trial. Inclusion criteria were:…

MECHANISMS OF HOPEAPHENOL INHIBITION OF HIV PROVIRUS FOLLOWING DISCONTINUATION

People living with HIV (PLWH) on suppressive ART continue to harbor transcriptionally-active virus, which can lead to ongoing viral antigen production, long-term inflammation, and increased risk of age-related co-morbidities. Compounds that block viral transcription from infected CD4+ T-cells may help reduce co-morbidity risks arising from ongoing immune activation due to chronic viral antigens. J-Lat 10.6…

2DR VS 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD8+ RATIO RECOVERY

Accumulating evidence suggests that integrase strand-transfer inhibitors (INSTI)-based initial antiretroviral therapy (ART) results in greater CD4/CD8 ratio recovery compared to other regimens. However, it is unknown whether the treatment initiation with INSTI-based two-drug regimens (2DR) has a different impact on the CD4/CD8 ratio recovery compared to INSTI-based 3DR. We emulated a target trial to assess…